Trades on 2 secondary markets

Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the next generation of obesity and cardiometabolic care through a diversified pipeline of GLP-1 based therapies. Founded in 2024 and headquartered in Waltham, Massachusetts, its lead candidate ribupatide (KAI-9531) is a on

emerging 15.0 / 100 0 APIs View provider profile →
CompanyBiopharmaceuticalBiotechnologyPharmaceuticalsObesityMetabolic Health

Kailera Therapeutics is an API provider whose private shares are listed on 2 secondary markets: Forge Global, EquityZen.

Where It Trades

F Forge Global View listing → EZ EquityZen View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.